Search Results for: car t
US proposal to seek a “better understanding” of Switzerland’s implementation of the Nagoya Protocol receives chilly reception
*The author thanks Professor Marc Perlman (Brown University) for his comprehensive notes on the IGC deliberations of 3 June 2016.
WIPO IGC30: Clean and track-changed version of Facilitators’ text on Intellectual Property and Genetic Resources
In October 2015 the General Assembly of the World Intellectual Property Organization (WIPO) renewed the mandate of the the Intergovernmental Committee on Genetic Resources, Traditional Knowledge and Folklore (GRTKF):
WHA69: Resolution WHA69.23 on CEWG follow-up charts course for WHO’s work on R&D
Saturday, 28 May 2016
WHA69: Resolution WHA69.23 on CEWG follow-up charts course for WHO’s work on R&D
WHO to Colombia Minister of Health: Unaffordable drug prices are a legitimate reason for issuing a compulsory license
For more information, contact:
(U.S.) Andrew Goldman, KEI: andrew.goldman@keionline.org or +1 (202) 332-2670
(Colombia) Andrea Carolina Reyes Rojas, Misión Salud: subdireccion@mision-salud.org
(Colombia) Dr. Francisco Rossi, IFARMA: francisco_rossi@hotmail.com
(More on Colombia here: /colombia)
28 Organizations Ask President Obama to Support Colombian Compulsory License on Expensive Leukemia Drug
Contact:
(U.S.) Andrew Goldman, KEI: andrew.goldman@keionline.org or +1 (202) 332-2670
(Colombia) Andrea Carolina Reyes Rojas, Misión Salud: subdireccion@mision-salud.org
(Colombia) Dr. Francisco Rossi, IFARMA: francisco_rossi@hotmail.com
(More on Colombia here: /colombia)
Washington, DC — Today, 28 organizations that support the advancement of public health, as well as the successful continuation of the peace process in Colombia, urged President Obama to voice U.S. support for Colombia’s right to grant a compulsory license on an expensive leukemia drug. Continue Reading
15 House Dems Press USTR to Clarify Position on Compulsory Licensing of cancer drug patent in Colombia
Yesterday, fifteen House Democrats sent a letter to Ambassador Michael Froman at the United States Trade Representative to express serious concern that the United States officials have been pressuring Colombia to abandon the process of issuing a compulsory license on imatinib. The letter can be read here.
Senator Hatch Defends Pressure on Colombia in Interview Regarding Imatinib
Yesterday, Colombia’s W Radio aired an interview with Senator Orrin Hatch, R-Utah, where he was asked about the reports of pressure on Colombia from the Senate Finance Committee, which he chairs, with regard to the compulsory license process for the expensive leukemia drug, imatinib.
WHA 69: Colombian Minister of Health Calls on WHO to Support the Regulation of Drug Monopolies
(More on Colombia here: /colombia)
On May 24, 2016, Colombia’s Minister of Health, Alejandro Gaviria, made an intervention at the World Health Assembly that referred to the pressure Colombia has been facing with regard to the potential compulsory license for imatinib and called for the WHO to support members to ensure sustainable development through the regulation of pharmaceutical monopolies and promoting competition, transparency, and the rational use of drugs.
Continue Reading
Background FAQ on Glivec (imatinib) compulsory license in Colombia
(More on Colombia here: /colombia) For more information, contact: (U.S.) Andrew Goldman, KEI: andrew.goldman@keionline.org or +1 (202) 332-2670 (Colombia) Andrea Carolina Reyes Rojas, Misión Salud: subdireccion@mision-salud.org (Colombia) Dr. Francisco Rossi, IFARMA: francisco_rossi@hotmail.com Frequently Asked Questions What is happening in Colombia… Continue Reading